Generation Bio (GBIO)
(Delayed Data from NSDQ)
$2.59 USD
-0.05 (-1.89%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $2.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Generation Bio Co. [GBIO]
Reports for Purchase
Showing records 1 - 20 ( 48 total )
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Out with the Old (ce), In with the New (iq)DNA
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Potential Generational Shift in Genetic Medicines
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Moderna Deal Helps Get Closer to Proof of Concept
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Heading Into a New Generation with Two Novel ctLNPs
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D